石药集团：长效多肽产品组合授权阿斯利康，加速全球创新药布局-20260131

Investment Rating - The report does not explicitly state an investment rating for CSPC Pharmaceutical Group Core Insights - CSPC Pharmaceutical Group has entered into a strategic collaboration and licensing agreement with AstraZeneca, focusing on innovative peptide molecule discovery and long-acting delivery products [1][7] - AstraZeneca will receive exclusive global rights (excluding certain regions) to develop, manufacture, and commercialize innovative long-acting peptide drugs based on CSPC's technology platforms [2][8] - This collaboration marks the third partnership between CSPC and AstraZeneca, highlighting CSPC's competitive edge in innovative drug development [4][11] Financial Terms - AstraZeneca will pay a total upfront payment of USD 1.2 billion, with CSPC Jushi Biomedicine receiving 35% of this amount [3][9] - AstraZeneca is also committed to milestone payments of up to USD 3.5 billion for development and up to USD 13.8 billion for sales, with CSPC Jushi Biomedicine entitled to receive payments based on pipeline progress [3][10] - Additionally, AstraZeneca will pay tiered royalties up to the low-double digits on net sales of all licensed products [3][10] Collaboration Framework - The collaboration includes one clinical-ready asset, SYH2082, which is a long-acting GLP-1R/GIPR dual agonist advancing to Phase I clinical trials, and three preclinical-stage research projects [8] - The partnership will also explore four additional new projects based on the established technology platforms [2][8] Pipeline and Future Outlook - CSPC's pipeline includes high-quality assets such as an EGFR ADC, a PDE4B inhibitor, and ACTIIA/ACTIIB monoclonal antibodies, with over 20 innovative drug assets entering clinical stages annually [4][12] - The report expresses optimism regarding the sustained global competitiveness and future out-licensing opportunities for CSPC's other assets [12]